BCAL DiagnosticsASX:BDX -5.33% EBIT per Share is A$-0.02 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 168 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 76.19% on this metric.
BCAL Diagnostics's EBIT per Share for the
six
months ended in Dec. 2025 was A$-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
During the past 3 years, the average EBIT per Share Growth Rate was -11.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BCAL Diagnostics's EBIT per Share or its related term are showing as below:
ASX:BDX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -11.9 Med: -11.9 Max: -11.9
Current: -11.9
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of BCAL Diagnostics was -11.90% per year. The lowest was -11.90% per year. And the median was -11.90% per year.
ASX:BDX's 3-Year EBIT Growth Rate is ranked worse than 76.19% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.1
vs ASX:BDX: -11.90
BCAL Diagnostics (ASX:BDX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BCAL Diagnostics EBIT per Share Related Terms
BCAL Diagnostics EBIT per Share Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAL Diagnostics (ASX:BDX) has a EBIT per Share of A$-0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #128 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 76.2%.
Is BCAL Diagnostics' EBIT per Share too high?
BCAL Diagnostics' current EBIT per Share is A$-0.02. Based on the distribution chart, BCAL Diagnostics ranks #128 out of 168 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does BCAL Diagnostics' EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #128 out of 168 companies for EBIT per Share. This places BCAL Diagnostics in the lower half of its industry. The industry median EBIT per Share is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current EBIT per Share is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current EBIT per Share of A$-0.02. The current EBIT per Share is A$-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current EBIT per Share is A$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 